Coronary Artery Disease
Conditions
Keywords
PCI, pVAD
Brief summary
The purpose of this study is to collect data on safety and device performance on the CSI pVAD System used to support hemodynamic stability during HR-PCIs to inform device design and finalization.
Interventions
DEVICECSI pVAD System
The CSI percutaneous ventricular assist device (pVAD) is being investigated as a temporary left ventricular system intended to support and/or provide hemodynamic stability during high-risk percutaneous coronary interventions.
Sponsors
Abbott Medical Devices
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DEVICE_FEASIBILITY
Masking
NONE
Intervention model description
This is a prospective, single-arm, single-site study.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Subject is ≥18 years of age 2. In the investigator's opinion, the subject is capable of providing informed consent. 3. Subject has signed the Independent Ethics Committee (IEC) approved study Informed Consent Form (ICF) prior to any study related procedures 4. Subject has a life expectancy ≥1 year 5. Subject has a left ventricular ejection fraction (LVEF) ≥15% and ≤40% 6. Subject has a planned elective or urgent high risk percutaneous coronary intervention with hemodynamic support 7. Subject of child bearing potential has a negative pregnancy test result
Exclusion criteria
1. Subject has ST-Elevation Myocardial Infarction (STEMI) within 30 days prior to study procedure based on criteria in SCAI definition 2. Subject has NSTEMI with cardiac enzymes that are not trending downward within 30 days prior to study procedure 3. Subject with RV failure (defined as reduced RV function on imaging and evidence of increased CVP \>18 mmHg) 4. Subject with history of cardiac arrest within 30 days prior to study procedure requiring cardiopulmonary resuscitation OR any history of cardiac arrest with impairment in mental status, cognition or any global or functional neurological deficit 5. Subject is in cardiogenic shock (defined as systolic BP \<90 mmHg, cardiac index \<2.1 and/or evidence of impaired end organ perfusion) that is not responsive to fluid infusion or requiring any inotropic or pressor support 6. Subject received any pressors or inotropes within 24 hours prior to the start of the study procedure 7. Subject has evidence of current or prior endocarditis 8. Subject with active myocarditis 9. Subject had a deep vein thrombosis (DVT) or pulmonary embolism (PE) within 6 months prior to study procedure 10. Subject had a stroke or TIA within 6 months prior to study procedure 11. Subject had previous CABG within 6 months prior to study procedure 12. Subject had coronary intervention within 30 days prior to study procedure 13. Subject has a coronary intervention planned within 30 days post procedure 14. Subject has presence of left ventricular (LV) mural thrombus 15. Subject has history of valve replacement or repair (e.g., MitraClipTM) including transcatheter edge to edge repair (TEER) 16. Subject has significant mitral valve disease (defined as mitral regurgitation greater than moderate, grade ≥2+ by echocardiogram (ECHO), mitral stenosis with MVA \<1.5 cm2) or has evidence of structural damage to the chordae tendineae or valve 17. Subject has significant aortic valve disease (defined as aortic stenosis (valve area ≤1.5 cm2 or moderate or severe aortic regurgitation (grade ≥2+ by ECHO)) 18. Subject with atrial fibrillation present at the time of enrollment or any time prior to RHC or CSI pVAD device placement 19. Subject has sustained tachycardia with heart rate over 120 BPM 20. Subject has sustained ventricular tachycardia either pre- or during intervention 21. Subject has severe pulmonary hypertension, defined as mean pulmonary artery pressure ≥40 mmHg 22. Subject has presence of an aneurysm or dissection along vascular delivery path including: 1. Abdominal aortic aneurysm 4.0 cm or greater, OR 2. Significant descending thoracic aortic aneurysm greater than 4.5 cm, OR 3. Any dissection of the ascending, transverse, or descending aorta 23. Subject has severe peripheral vascular disease that will preclude the use of a 12Fr access sheath, which is required for the insertion of the CSI pVAD catheter 24. Subject has severe aortic tortuosity 25. Subject has severe aortic calcification that may preclude appropriate placement of the CSI pVAD device 26. Subject's vasculature will not tolerate a right heart catheterization (RHC) 27. Subject has chronic renal dysfunction defined by either: 1. Serum creatinine ≥ 2.5 mg/dl AND/OR 2. Requires hemodialysis 28. Subject has liver dysfunction with either: 1. Elevation of liver enzymes and bilirubin levels to ≥ 3X ULN OR 2. Internationalized Normalized Ratio (INR) ≥ 2 OR 3. Lactate dehydrogenase (LDH) \> 2.5X ULN 29. Subject has uncorrectable abnormal coagulation parameters defined as either: 1. Platelet count ≤75,000 per μL OR 2. INR ≥2.0 or 30. Subject has history of heparin induced thrombocytopenia 31. Subject has history of bleeding diathesis or known coagulopathy, any recent GU or GI bleed within 30 days prior to study procedure or will refuse blood transfusions 32. Subject has anemia (hemoglobin \<10.0 g/dL) or polycythemia/hypovolemia (hemoglobin \>16.5 g/dL) 33. Subject requires, or, in the clinical judgement of the investigators may need, long term support (\>6 hours) with a commercially available mechanical circulatory support (MCS) device 34. Subject was on any mechanical cardiac support device at any time within 14 days prior to the study procedure. 35. Subject has an active systemic infection requiring oral or intravenous antibiotics, or elevated temperature or white blood cell count that may be due to infection 36. Subject has been diagnosed with COVID ≤10 days prior to study procedure or is excluded due to COVID based on institution or other (e.g., CDC) guidelines 37. Subject has an allergy or intolerance to ionic and nonionic contrast media, anticoagulants, or antiplatelet therapy drugs that cannot be adequately premedicated 38. Subject has an allergy or intolerance to CSI pVAD System components 39. Subject is pregnant 40. Subject is currently participating or plans to participate in another investigational drug- or device trial that may affect any of this study's endpoints 41. Subject has any other anatomical-, clinical-, social-, etc. characteristics that preclude the subject from being a candidate for the study 42. Subject has any contradiction listed in the current IFU
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| CSI pVAD System device placement/procedural success | Intraprocedural | Delivery of the device to the correct anatomical position, successful operation and removal of the CSI pVAD system |
| Prevention of severe hypotension while on CSI pVAD device support | Intraprocedural | Percentage of subjects who were free from severe hypotension while on CSI pVAD device support. |
| Major Device-Related Adverse Events | from Intraprocedure through study exit at 30 day follow up | Percentage of subjects who were free from: * Access site complications, defined as complications requiring unplanned transfusion of packed red blood cells (1 unit or more) and/or percutaneous or surgical intervention * Bleeding (BARC category 3 or 5, and category 2 if serious criterion is met) * Cardiovascular death * Clinically significant myocardial infarction (MI), classified based on the SCAI and Fourth Universal definitions * Stroke (ischemic or hemorrhagic), classified based on symptoms on CT or MRI imaging |
Countries
Georgia
Outcome results
None listed